Resolution

Gemeinsamer Bundesausschuss

of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM-RL): Annex XII – Amendment of Information on the Period of Validity of a Resolution on the Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V Ixazomib

of 5 September 2019

At its session on 5 September 2019, the Federal Joint Committee (G-BA) resolved to amend the Directive on the Prescription of Medicinal Products in SHI-accredited Medical Care (Pharmaceuticals Directive, AM-RL) in the version dated 18 December 2008/22 January 2009 (Federal Gazette, BAnz. No. 49a of 31 March 2009), last amended on D Month YYY (Federal Gazette, BAnz AT DD.MM.YYYY BX), as follows:

I. In Annex XII, the provision under II. 2. concerning the period of validity of the resolution on the benefit assessment ixazomib of 6 July 2017 shall be amended as follows:

The entry “1 July 2020”, which entered into force with the resolution of 6 July 2017, shall be replaced by “1 August 2021”.

II. The resolution will enter into force on the day of its publication on the internet on the website of the G-BA on 5 September 2019.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de .

Berlin, 5 September 2019

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The chair

Prof Hecken